Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Mivebresib Alone or in Combination With Ruxolitinib or Navitoclax in Subjects With Myelofibrosis

NCT04480086 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04480086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Mivebresib Alone or in Combination With Ruxolitinib or Navitoclax in Subjects With Myelofibrosis
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
March 17, 2021
Completion date
July 28, 2023
Enrollment
1 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis (mf)